Browsing Tag
SHASTA-3
1 post
From rare disease to mass market: plozasiran gets FDA green light for severe hypertriglyceridemia review
Arrowhead’s plozasiran receives FDA Breakthrough Therapy status for severe hypertriglyceridemia. Learn what this means for trials, patients, and the RNAi market.